Home
overview

According to a recent Frost & Sullivan report, "The global IVD market has shown a consistent growth of 6.72 percent annually, a trend that is expected to continue until 2012."

The IVD market remains to be one of the most promising markets in the world.

SMi's 2nd annual In Vitro Diagnostics conference will provide an integral forum to leaders in biotech, pharma and labs to discuss the value of diagnostics and overcome challenges posed by regulatory bodies. Make sure you attend this event and successfully align your business strategies for potential opportunities.

 

 

  • Understand the key trends and developments that are driving the In Vitro Diagnostics market globally
     
  • Analyse the most viable In Vitro diagnostics sectors to successfully align your future strategies
     
  • Assess and overcome the challenges faced by diagnostic companies in the current times
     
  • Make informed business decisions by benchmarking yourself against other industry leaders
 

 

  • Directors of Molecular Genetics
  • Global Diagnostics Managers
  • Heads of IVD
  • Heads of Molecular Medicine
  • Heads of Molecular Diagnostics

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

David Huckle

David Huckle, Chief Executive, Adams Business Associates

9:10 ANALYSING KEY IVD MARKET DRIVERS

David Huckle

David Huckle, Chief Executive, Adams Business Associates

  • Impact on growth of Regulations, Reimbursement & Health Technology Assessment
  • Newly developed markets
  • IVD  market forecasts in a recessionary economy
     
  • 9:50 EMERGING TRENDS IN IMMUNO AND MOLECULAR DIAGNOSTICS

    Eddie Blair

    Eddie Blair, Director, Integrated Medicines Ltd

  • Molecular diagnostics in personalised medicine
  • Companion Diagnostics
  • Future trends
  • 10:30 Morning Coffee

    10:50 DELIVERING ON THE PROMISE OF PERSONALIZED HEALTHCARE

    Ansar Jawaid

    Ansar Jawaid, Global Diagnostics Manager, AstraZeneca

  • Overview of Personalized Healthcare
  • Challenges across the value chain
  • Examples from AstraZeneca
  • 11:30 UNDERSTANDING THE ROLE AND IMPACT OF NEW TECHNOLOGIES IN POINT OF CARE TESTING

    Anthony James

    Anthony James, Technology Adoption Associate, NHS Institute for Innovation and Improvement

  • Technology Review – Current status
  • Technology Review – Developing and Future Technologies.
  • Pathway changes & affect on Implementation
  • Role of Health Technology Assessment (HTA)
  • 12:10 A NEW ACCURATE AND ROBUST, PCR, PROPRIETARY MOLECULAR BIOLOGY METHOD FOR MULTIPLEX DIAGNOSTICS

    Ray Harrison

    Ray Harrison, Chief Executive Officer, Point-2-Point Genomics Ltd

  • Method has potential to detect any bacteria, mycobacteria or fungi
  • Can resolve up to 2 to the power 10 = 1024 bacterial types in one well
  • Can return up results in up to 2 hours
  • UK Government SMART Award winning technology
  • 12:30 PRICING AND REIMBURSEMENT STRATEGY FOR IN VITRO DIAGNOSTICS

    Gerald  Schnell

    Gerald Schnell , Partner, Simon-Kucher & Partners

  • Common pitfalls in P&R for in vitro diagnostics
  • Profiling the product's clinical and economic value is a key requirement
  • A structured approach to developing the optimal P&R strategy
  • International dimension of the P&R strategy
  • 13:10 Networking Lunch

    14:10 DRIVERS OF SUPPLY & DEMAND FOR DIAGNOSTICS

    Devaki Nair

    Devaki Nair, Consultant Clinical Pathologist, Royal Free Hospital

  • Diagnostics for health checks- the need for POCT
  • Problems in the past- re quality/technology etc
  • Current  Situation 
  • What more we need under future
  • 14:50 CLINICALLY USEFUL POINT-OF-CARE DIAGNOSTICS FOR INFECTIOUS DISEASES

    Penny Wilson

    Penny Wilson, Lead Specialist, Detection and Identification Of Infectious Agents, Technology Strategy Board

  • The Technology Strategy Board’s Innovation Platform on the Detection & Identification of Infectious Agents
  • Why Point-of-Care? Challenges and opportunities
  • Emerging technologies and capabilities
  • 15:30 Afternoon Tea

    15:50 IVD INDUSTRY GUIDELINES, STUDY DESIGN & ANALYSIS CONSIDERATIONS

    Vicki Petrides

    Vicki Petrides, Statistician Section Head, Diagnostics Division, Abbott

  • References and guidelines to follow during research & development
  • Critical experimental design considerations not necessarily addressed in guidelines
  • Common study design and data analysis mistakes
     
  • 16:30 THE PROCESS OF MARKET SURVEILLANCE AND AUDITING

    Elaine Mooney

    Elaine Mooney, Scientific Officer IVD’s, Irish Medicines Board

  • Post market surveillance of IVDs
  • Vigilance MEDDEV
  • Compliance issues

     

  • 17:10 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    David Huckle

    David Huckle, Chief Executive, Adams Business Associates

    9:10 FUTURE OF DIAGNOSTIC TESTS IN CLINICAL PRACTICE FOR PERSONALIZED MEDICINE

    Anil Modak

    Anil Modak, Associate Director, Medical Products Research & Development, Cambridge Isotope Laboratories Inc.

  • Current and future status of in vivo and in vitro tests as point of care diagnostic tools
  • Future of non invasive breath tests in personalized medicine.
  • Companion diagnostic tests for individualized therapy.
  • Challenges in getting diagnostic tests into routine clinical practice
  • 9:50 HOW DO PHARMA/BIOTECH COMPANIES ACQUIRE PERSONALISED MEDICINE TECHNOLOGIES

    Adrian  Dawkes

    Adrian Dawkes, Senior Director, Pharma Ventures

  • Deal trends in pharma/biotech - where do biomarkers and diagnostics fit in?
  • Strategies and business models
  • Success stories and the future
  • 10:30 APPLYING MICROFLUIDICS TO ENABLE POINT-OF-CARE IMMUNODIAGNOSTICS

    Holger Bartos

    Holger Bartos, Director of Marketing and Sales, Boehringer Ingelheim Microparts Gmbh

  • Integration of typical assay steps
  • Cost efficient production of Biochips
  • Rapid assay results with high sensitivity
  • 11:10 Morning Coffee

    11:30 THE INTRODUCTION OF DIAGNOSTICS FOR PERSONALISED MEDICINE IN THE UK NATIONAL HEALTH SERVICE

    Rob Elles

    Rob Elles, Director of Molecular Genetics, National Genetics Reference Lab, Manchester

  • An overview of UK National Health Service biomedical diagnostics
  • How the NHS introduces new molecular genetic testing services
  • Examples of NHS delivery of personalized medicine diagnostics
  • 12:10 OPPORTUNITIES FOR NEW BIOCHIP TECHNOLOGY IN LABORATORY & POINT OF CARE TESTING

    Till Bachmann

    Till Bachmann, COO, Head of Biochip Research, University of Edinburgh

  • Biochips for infectious disease stratification and therapy selection
  • Importance of pathogen, drug and host for diagnostics
  • Rapid pathogen and antibiotic resistance testing
  • 12:50 Networking Lunch

    13:50 IMPROVING MOLECULAR DIAGNOSTICS THROUGH BIOCHIPS AND NANOTECHNOLOGY

    Moncef Benkhalifa

    Moncef Benkhalifa, Director, ATL R&D, Unilabs France

  • Gene investigation in R&D and clinical molecular diagnostics
  • Pre-implantation genetic diagnosis
  • Post and prenatal diagnosis
  • Future of micro arrays and nanotechnology
     
  • 14:30 FROM EARLY DEVELOPMENT TO PROOF OF CONCEPT: KEY ASPECTS OF THE POC STUDY

    Michael-Friedrich Boettcher

    Michael-Friedrich Boettcher, Study Manager and Coordinator, Bayer A G

  • Strategic aspects
  • Is it possible to combine PoC with first in man (FiM) studies?
  • What is the optimal time point to perform a PoC-study?
  • Implementing a PoC (point of care test) into a PoC-study
  • 15:10 EMERGENCE OF NON TRADITIONAL STAKEHOLDERS IN THE IVD INDUSTRY

    Harry Glorikian

    Harry Glorikian, Managing Partner, Scientia Advisors

  • In vitro diagnostics is seeing a dramatic increase in the number of stakeholders actively engaging in promoting and furthering its use in the delivery of healthcare for patients
  • In addition to traditional stakeholders such as regulator, payors, physicians, lab directors, and patients a new set of stakeholders are emerging to influence the industry
  • Pharmaceutical companies, Pharmacy Benefit Managers, Health IT companies, and Life Science Tools companies are some key emerging stakeholders that are expected to have a dramatic impact on the industry
  • 15:50 Chairman’s Closing Remarks and Afternoon Tea

    16:00 Close of Conference

    +

    Workshops

    Development of IVD SMEs. What are the business models and are they viable?
    Workshop

    Development of IVD SMEs. What are the business models and are they viable?

    Crowne Plaza Hotel - St James
    14th July 2010
    London, United Kingdom

    Crowne Plaza Hotel - St James

    Buckingham Gate 45/51
    London SW1E 6AF
    United Kingdom

    Crowne Plaza Hotel - St James

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.